BCL2 and breast cancer: In another study involving siRNA knockdown targeting the AKT in MCF-7 human breast cancer cell line, the introduction of the siRNA has reduced the expression of AKT and BCL-2 (anti-apoptotic protein) proteins, which may enhance the probability of cancer cell death [40].